Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare

Drugmakers appear to be less concerned about the impact of negotiated prices on their businesses in the short term. Meanwhile, health care heads to Hollywood.

Previous post Rivian tops Wall Street’s second-quarter expectations amid cost cuts
Next post Upstart’s stock soars as fintech company’s CEO says comeback is in the works